Latest News
Galderma secures Chinese approval for Relfydess to treat frown lines
23 October 2026 - Dermatology company Galderma (SIX:GALD) said on Friday that it has received approval from China's National Medical Products Administration for Relfydess (relabotulinumtoxinA) to temporarily improve moderate-to-severe frown line...
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
23 October 2026 - RNAi (RNA interference) therapeutics company Alnylam Pharmaceuticals Inc (Nasdaq:ALNY) on Friday reported positive initial Phase 1b clinical trial results for brezosiran, an investigational RNAi therapy for Huntington's disease...
Zai Lab reports promising Phase 1b results for zocilurtatug pelitecan in small cell lung cancer
23 October 2026 - Zai Lab Limited (NASDAQ:ZLAB) (HKEX:9688), a research-based, commercial-stage biopharmaceutical company based in China and the United States, on Friday reported promising initial results from a global Phase 1b trial evaluating zocil...
Labcorp, Charles River and FDA collaborate on advancing preclinical methods for evaluating drug abuse potential
23 October 2026 - Laboratory services provider Labcorp (NYSE:LH) announced on Thursday a collaboration with the US Food and Drug Administration (FDA) and pharmaceutical research services provider Charles River Laboratories International Inc (NYSE:CRL...
HUYABIO International reports positive Phase 3 trial results for HBI-8000 and nivolumab combination
23 October 2026 - Biopharmaceutical company HUYABIO International announced on Thursday that oral HBI-8000 in combination with intravenous nivolumab reduced the risk of disease progression or death by 27% compared with nivolumab alone in a global Pha...